Zumutor Biologics, an Immuno-Oncology company, has raised $4 million in series A2 funding led by new investor Bharat Innovation Fund (BIF). The round also saw participation from its existing investor Accel Partners. With this round, the total funding raised by the startup stands at around $20 million. The company was founded in 2015 by Kavitha Iyer Rodrigues.
Earlier, the company had raised capital from Chiratae Ventures, Aarin Capital, and Karnataka Information Technology Venture Capital Fund (KITVEN).
Founder and CEO, Zumutor Biologics, Kavitha Iyer Rodrigues said, “Our first-in-class lead molecule ZM 008 has made industry validated progress and is poised for IND filing with Phase 1a/1b clinical trials likely to commence end 2020. Series A2 funding will enable pivotal milestones in development stages.”
Zumutor is a leading Immuno-Oncology company in the space of targeted NK cell therapeutics. They have two proprietary Antibody Engineering Platforms to develop novel immunotherapies that target innate immunity and regulate the tumor microenvironment.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.